Conjunctivitis Treatment Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

Conjunctivitis Treatment Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

The conjunctivitis treatment market is expected to register a CAGR of 4.1% over the forecast period.

COVID-19 had a significant impact on the growth of the market during the pandemic period. This is due to the probable frequency of conjunctivitis conditions in coronavirus-infected patients. According to the NCBI article published in August 2021, conjunctivitis can manifest in COVID-19-infected people. Thus, increasing attention toward conjunctivitis during the pandemic had the potential to drive the demand for the market. However, the relaxation of strict lockdowns is expected to increase the patient inflow for conjunctivitis treatment procedures and contribute to the growth of the market studied over the next five years.

The market studied is expected to grow in the forecast period due to the high number of people suffering from conjunctivitis and the easier availability of treatment across the globe. According to the NCBI article published in April 2021, one of the most common ocular disorders among participants was allergic conjunctivitis, with 1.3%. As the disease is very common, hence, treatment is readily available.

Generally, conjunctivitis is self-diagnosable, and there is the least need to undergo any diagnostic test for this disease. Thus the incidence of allergic conjunctivitis is expected to contribute to the market's growth during the forecast period. As per another NIH article published in February 2021, viral and bacterial conjunctivitis are the two common forms of infectious conjunctivitis, with viral infection responsible for up to 80% of all acute conjunctivitis cases and bacterial infection accounting for between 50-75% of cases of infectious conjunctivitis in children. According to the same source, countries like China also have a high incidence of conjunctivitis. Moreover, as per the BMC article published in March 2022, the average annual hemorrhagic conjunctivitis incidence was 3.58/100,000 in mainland China. The rising incidence of hemorrhagic conjunctivitis is expected to drive the demand for conjunctivitis treatment, thereby contributing to market growth.

Hence, owing to the abovementioned factors, the market studied is expected to have steady growth over the forecast period.

Allergic conjunctivitis is expected to hold a significant market share over the forecast period. Allergic conjunctivitis is common and causes sudden swelling in the eyelids and ocular itching. People having allergies are more likely to develop allergic conjunctivitis.

As per the Nature article published in April 2022, approximately 10% of the sample population had allergic conjunctivitis. In India, the prevalence of allergic conjunctivitis was 12.22% among those aged between five and 15 years. Also, the NCBI article published in January 2021 mentioned that more than half of the patients report daily symptoms as seasonal or perennial and around 75% consider their symptoms to be severe. The same source also mentioned that there were between 1.2 and 10.6 cases of vernal keratoconjunctivitis per 10,000 individuals in Europe. Such incidence of allergic conjunctivitis is expected to drive the demand for effective treatment, contributing to the growth of the studied segment.

Treatment for acute conjunctivitis includes oral or over-the-counter (OTC) drugs that reduce the release of histamine. Also, anti-inflammatory or anti-inflammation eye drops are available quickly and are found to relieve acute conjunctivitis. Hence, this segment is expected to witness steady growth during the forecast period.

North America is expected to dominate the market, owing to factors such as the easy availability of effective treatment products and high awareness among consumers regarding conjunctivitis in the region. As per the National Library Medicine article published in February 2020, conjunctivitis affects more than 6 million people across United States every year. The estimated cost for the disease is around USD 377 million to USD 857 million per year. Conjunctivitis is found to be the most frequent disease in the country and affects 15% to 40% of the population, and is seen frequently in spring and summer.

Also, the NCBI article published in January 2021 mentioned that seasonal or perennial allergic conjunctivitis is the most prevalent form of allergic conjunctivitis, with more than 95% of ocular allergy cases in United States. It is observed in both sexes and affects between 15% and 40% of the population. Such prevalence of conjunctivitis in United States is expected to drive the demand for effective treatment, thereby contributing to the market's growth during the forecast period.

Due to better healthcare services and the high number of people suffering from conjunctivitis in United States, the market is expected to hold the largest share shortly.

Also, the high prevalence of conjunctivitis in Canada is expected to contribute to the market's growth over the forecast period. As per the BMC article published in October 2022, it is estimated that 21% of Canadians have dry eyes. Such prevalence of conjunctivitis is expected to contribute to market growth in Canada.

Similarly, the high prevalence of conjunctivitis is expected to contribute to the driving demand for conjunctivitis treatment. As per the World Allergy Organization Journal published in December 2020, 10 medical centers reported a prevalence of allergic rhinoconjunctivitis in children of 11.6%, while adolescents reported 15.4%. Such prevalence of conjunctivitis in Mexico is expected to contribute to the market's growth.

Thus, the factors mentioned above are expected to drive the market's growth during this region's forecast period.

The conjunctivitis treatment market is moderately consolidated in nature due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international and local companies which hold market shares and are well known, including Allergan, Alembic Pharmaceuticals, Bausch & Lomb Incorporated, Novartis, NicOx SA, and others.

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support